Exendin(9-39)amide Is an Antagonist of Glucagon-like Peptide-1(7-36)amide in Humans

Jörg Schirra, Kerstin Sturm, Petra Leicht, Rudolf Arnold, Burkhard Göke, and Martin Katschinski
Clinical Research Unit for Gastrointestinal Endocrinology and Department of Gastroenterology and Endocrinology, Philipps University, 35033 Marburg, Germany

Abstract

The gastrointestinal hormone, glucagon-like peptide-1(7-36)amide (GLP-1) is released after a meal. The potency of synthetic GLP-1 in stimulating insulin secretion and in inhibiting glucagon secretion indicates the putative physiological function of GLP-1. In vitro, the nonmammalian peptide, exendin(9-39)amide [ex(9-39)NH$_2$], is a specific and competitive antagonist of GLP-1. This in vivo study examined the efficacy of ex(9-39)NH$_2$ as an antagonist of exogenous GLP-1 and the physiological role of endogenous GLP-1. Six healthy volunteers underwent 10 experiments in random order. In each experiment, a 30-min period of euglycemia was followed by an intravenous infusion of glucose for 150 min that established a stable hyperglycemia of 8 mmol/liter. There was a concomitant intravenous infusion of one of the following: (1) saline, (2) GLP-1 (for 60 min at 0.3 pmol ⋅ kg$^{-1}$ ⋅ min$^{-1}$) that established physiological postprandial plasma levels, and for another 60 min at 0.9 pmol ⋅ kg$^{-1}$ ⋅ min$^{-1}$ to induce supraphysiological plasma levels), (3–5) ex(9-39)NH$_2$ at 30, 60, or 300 pmol ⋅ kg$^{-1}$ ⋅ min$^{-1}$ + GLP-1, (6–8) ex(9-39)NH$_2$ at 30, 60, or 300 pmol ⋅ kg$^{-1}$ ⋅ min$^{-1}$ + saline, (9 and 10) GIP (glucose-dependent insulinotropic peptide; for 60 min at 0.8 pmol ⋅ kg$^{-1}$ ⋅ min$^{-1}$, with saline or ex(9-39)NH$_2$ at 300 pmol ⋅ kg$^{-1}$ ⋅ min$^{-1}$). Each volunteer received each of these concomitant infusions on separate days. ex(9-39)NH$_2$ dose-dependently reduced the insulinoergic action of GLP-1 with the inhibitory effect declining with increasing doses of GLP-1. ex(9-39)NH$_2$ at 300 pmol ⋅ kg$^{-1}$ ⋅ min$^{-1}$ blocked the insulinoergic effect of physiological doses of GLP-1 and completely antagonized the glucagonostatic effect at both doses of GLP-1. Given alone, this load of ex(9-39)NH$_2$ increased plasma glucagon levels during euglycemia and hyperglycemia. It had no effect on plasma levels of insulin during euglycemia but decreased plasma insulin during hyperglycemia. ex(9-39)NH$_2$ did not alter GIP-stimulated insulin secretion. These data indicate that in humans, ex(9-39)NH$_2$ is a potent GLP-1 antagonist without any agonistic properties. The pancreatic A cell is under a tonic inhibitory control of GLP-1. At hyperglycemia, the B cell is under a tonic stimulatory control of GLP-1. (J. Clin. Invest. 1998. 101:1421–1430.) Key words: GLP-1 · exendin(9-39)amide · insulin · glucagon · entero-insular axis

Introduction

The proglucagon-derived glucagon-like peptide-1(7-36)amide (GLP-1)$^1$ is a gastrointestinal hormone that is released postprandially from the L cells of the gut (1–3) and exerts a glucose-dependent and direct insulinoergic effect on the pancreatic B cell. It acts via specific receptors, which activate adenylate cyclase (4), and enhances insulin secretion and biosynthesis (3, 5, 6). In addition, synthetic GLP-1 has been shown in vitro and in vivo to reduce glucagon secretion (7–12). It may also enhance glucose uptake in peripheral tissues (13, 14). These combined effects improve glucose tolerance and are the rationale for evaluating the peptide’s therapeutic potential in the treatment of diabetes mellitus (8, 11, 15). Furthermore, studies in humans indicated an inhibitory role for GLP-1 in the control of gastric emptying and antroduodenal motility (12, 16, 17), gastric acid secretion (17–19), and satiety (20). Taken together, studies so far indicate that GLP-1 plays a crucial role in integrating postprandial events.

It is a classic and essential requirement in endocrinology to use specific inhibition of the putative endogenous hormone by receptor blockade to evaluate physiological relevance. Recently, a derivative of the nonmammalian peptide, exendin-4, exendin(9-39)amide [ex(9-39)NH$_2$], has been found to act as a specific and competitive antagonist at the GLP-1 receptor (21–24). The peptide was isolated from the venom of the lizard Heloderma suspectum and the truncated form, ex(9-39)NH$_2$, shares 53% sequence homology to GLP-1(7-36)amide (23). ex(9-39)NH$_2$ has been applied already in animal experiments. The effect of its intracerebroventricular injection in rats has implicated that GLP-1 acts as a central regulator of satiety as well as of water and salt homeostasis (25, 26). Intravenous application of ex(9-39)NH$_2$ in rats has been used to demonstrate that GLP-1 is an important enhancer of postprandial insulin release and, therefore, functions as a true incretin hormone in this species (27, 28). Also, in the baboon, antagonism of circulating GLP-1 by ex(9-39)NH$_2$ impaired the disposal of intragastroic glucose, as did immunoneutralization of GLP-1, and

---

1. Abbreviations used in this paper: ex(9-39)NH$_2$, exendin(9-39)amide; GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide-1; IR, immunoreactive.
this was, in part, due to diminished insulin release in the early postprandial phase (29).

So far, an antagonist of GLP-1 has not been investigated in humans. Therefore, this study was designed to assess the efficacy of ex(9-39)NH$_2$ as an antagonist of GLP-1(7-36)amide in men and the endocrine effects of ex(9-39)NH$_2$ per se. We examined the effects of increasing doses of ex(9-39)NH$_2$ during euglycemia and during physiological hyperglycemia with or without varying doses of exogenous GLP-1(7-36)amide on glucose disposal and on insulin and glucagon release.

**Methods**

**Subjects.** Six healthy male volunteers, 23–27 yr of age and within 5% of ideal body weight, participated in the study. None of them had a family history of diabetes mellitus or was under any medication. The studies were approved by the Ethical Committee of the Medical Faculty of the Philipps University of Marburg, and all participants provided written informed consent.

**Experimental protocol.** All studies were performed after an overnight fast. Experiments in individual subjects were separated by intervals of at least 1 wk. In the morning of each study, an indwelling catheter was inserted into an antecubital vein for infusion of hormones and glucose. A second catheter was inserted in a retrograde fashion into a dorsal vein of the contralateral hand. This hand was continuously warmed throughout each experiment to exactly 40°C by an infrared lamp regulated by a sensor-controlled biothermostat to arterilize the venous blood (“heated hand”).

Table I. Experimental Design of the Study

<table>
<thead>
<tr>
<th>Study days</th>
<th>GLP-1 i.v.</th>
<th>GIP i.v.</th>
<th>ex(9-39) NH$_2$ i.v.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(random order)</td>
<td>pmol · kg$^{-1}$ · min$^{-1}$</td>
<td>pmol · kg$^{-1}$ · min$^{-1}$</td>
<td>pmol · kg$^{-1}$ · min$^{-1}$</td>
</tr>
<tr>
<td>1</td>
<td>Saline</td>
<td>—</td>
<td>Saline</td>
</tr>
<tr>
<td>2</td>
<td>0.3 and 0.9</td>
<td>—</td>
<td>Saline</td>
</tr>
<tr>
<td>3</td>
<td>0.3 and 0.9</td>
<td>—</td>
<td>30</td>
</tr>
<tr>
<td>4</td>
<td>0.3 and 0.9</td>
<td>—</td>
<td>60</td>
</tr>
<tr>
<td>5</td>
<td>0.3 and 0.9</td>
<td>—</td>
<td>300</td>
</tr>
<tr>
<td>6</td>
<td>Saline</td>
<td>—</td>
<td>30</td>
</tr>
<tr>
<td>7</td>
<td>Saline</td>
<td>—</td>
<td>60</td>
</tr>
<tr>
<td>8</td>
<td>Saline</td>
<td>—</td>
<td>300</td>
</tr>
<tr>
<td>9</td>
<td>—</td>
<td>0.8</td>
<td>Saline</td>
</tr>
<tr>
<td>10</td>
<td>—</td>
<td>0.8</td>
<td>300</td>
</tr>
</tbody>
</table>

In each experiment, a 30-min period of euglycemia (−60 to −30 min) was followed by adjustment of blood glucose to 8 mmol/liter for 150 min using the glucose clamp technique. This was accomplished by a priming infusion of glucose over 15 min, followed by a variable infusion of a 20% glucose solution. Infusion rate adjustments were performed according to DeFronzo et al. (30) using a servo-controlled negative feedback formula based on 5-min blood glucose determinations, coupled to a variable speed infusion pump.

Each volunteer underwent 10 experiments in random order. Table I shows the experimental design of the study. On four separate days, GLP-1 was intravenously infused from 0 to 60 min at 0.3 pmol · kg$^{-1}$ · min$^{-1}$ to establish physiological postprandial plasma levels, and from 90 to 150 min at 0.9 pmol · kg$^{-1}$ · min$^{-1}$ to induce supraphysiological plasma levels. Each infusion period was preceded by a priming infusion of GLP-1 over 30 min. In these four experiments with GLP-1, 0.154 M NaCl and ex(9-39)NH$_2$ at 30, 60, or 300 pmol · kg$^{-1}$ · min$^{-1}$ were intravenously infused as background infusions throughout each experiment after a priming infusion over 60 min. On three other days, ex(9-39)NH$_2$ in combination with 0.154 M NaCl was infused at either 30, 60, or 300 pmol · kg$^{-1}$ · min$^{-1}$, respectively. In the experiments with 300 pmol · kg$^{-1}$ · min$^{-1}$ ex(9-39)NH$_2$/0.154 M NaCl, the duration of peptide infusion after the priming period was restricted to 60 min in order to save peptide. In two further experiments, glucose-dependent insulinotropic peptide (GIP) was infused from 0 to 60 min at 0.8 pmol · kg$^{-1}$ · min$^{-1}$ (priming period from −30 to 0 min) to establish physiological postprandial plasma levels, either with backgound infusion of 0.154 M NaCl or ex(9-39)NH$_2$ at 300 pmol · kg$^{-1}$ · min$^{-1}$. One study day with infusion of only 0.154 M NaCl served as control.

Blood samples were taken at −70, −60, −30, 0, 15, 30, 40, 50, 60, 90, 105, 120, 130, 140, and 150 min for determination of the plasma immunoreactivities of GLP-1, GIP, and glucagon. Determinations and assays. Blood glucose concentrations were measured by the glucose oxidase method using a glucose analyzer (YSI 1500 G; Schlach G, Bergisch-Gladbach, Germany). Plasma immunoreactivities of insulin, C-peptide, and glucagon were analyzed by commercially available radioimmunooassay kits (Biermann, Bad Nauheim, Germany). Immunoreactive (IR) GLP-1 was measured using the specific polyclonal antibody GA 1178 (Affinity Research, Nottingham, United Kingdom) as described previously (2). Immunoreactivities were extracted from plasma samples on C-18 cartridges using acetonitrile for elution of samples. The detection limit of the assay was 0.25 pmol/liter. The antiserum did not cross-react with ex(9-39)NH$_2$, GIP, pancreatic glucagon, glicentin, oxyntomodulin, or...
Exendin(9-39)amide in Humans

GLP-1. Intra- and interassay coefficients of variation were 3.8 and 10.9%, respectively.

Statistical analysis. All values were expressed as mean±SEM. Time courses of plasma hormones, glucose, and glucose infusion rate were represented by actual or incremental values over basal. Basal levels were determined as the mean of the two first values at the start of each experiment (−70 and −60 min). For low and high dose GLP-1, the effects of the different background infusions on plasma hormones, blood glucose, and glucose infusion rate were analyzed separately. Here, mean incremental plasma hormone and blood glucose levels over basal as well as mean glucose infusion rates during the last 45 min of each infusion period of GLP-1 were used for evaluation.

Figure 1. Immunoreactivities of GLP-1 in response to single or combined intravenous infusions of GLP-1(7-36)amide at 0.3 and 0.9 pmol·kg⁻¹·min⁻¹ and ex(9-39)NH₂ at 30 or 300 pmol·kg⁻¹·min⁻¹ in six healthy volunteers. Mean±SEM. For statistical analysis, see Tables II and III.

Figure 2. Infusion rates of exogenous glucose during glucose clamp at 8 mmol/liter in six healthy volunteers in response to single or combined intravenous infusions of GLP-1(7-36)amide at 0.3 and 0.9 pmol·kg⁻¹·min⁻¹ and ex(9-39)NH₂ at 30 or 300 pmol·kg⁻¹·min⁻¹. Mean±SEM. For statistical analysis, see Tables II and III.
Table II. Effect of Graded Doses of Intravenous ex(9-39)NH2 on Consumption of Exogenous Glucose, Blood Glucose Levels, and Plasma Immunoreactivities of GLP-1, Insulin, C-Peptide, and Glucagon against Intravenous Background Infusions of Saline or Postprandial Physiological Doses of GLP-1 or GIP during the First Infusion Period (0–60 min) of the Hyperglycemic Clamp (8 mmol/liter) in Healthy Subjects

<table>
<thead>
<tr>
<th>Combination of intravenous infusions</th>
<th>Blood glucose</th>
<th>IR-GLP-1*</th>
<th>Glucose infusion rate</th>
<th>IR-Insulin*</th>
<th>IR-C-peptide*</th>
<th>IR-Glucagon*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mmol/liter</td>
<td>pmol/liter</td>
<td>mg/kg · min</td>
<td>mL/liter</td>
<td>ng/ml</td>
<td>pg/ml</td>
</tr>
<tr>
<td>Saline i.v.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline + saline</td>
<td>8.0±0.03</td>
<td>−2.2±0.6</td>
<td>5.2±1.0</td>
<td>15.0±4.2</td>
<td>2.2±0.4</td>
<td>−17.2±1.7</td>
</tr>
<tr>
<td>Saline + ex(9-39)NH2 30</td>
<td>8.0±0.07</td>
<td>−1.2±0.5</td>
<td>4.7±0.4</td>
<td>15.5±3.1</td>
<td>2.1±0.3</td>
<td>−14.5±4.2</td>
</tr>
<tr>
<td>Saline + ex(9-39)NH2 60</td>
<td>8.0±0.03</td>
<td>−1.9±0.6</td>
<td>4.5±0.4</td>
<td>14.9±5.0</td>
<td>2.7±0.7</td>
<td>−9.3±4.0</td>
</tr>
<tr>
<td>Saline + ex(9-39)NH2 300</td>
<td>8.0±0.03</td>
<td>−1.0±0.2</td>
<td>4.0±0.8</td>
<td>8.6±1.5</td>
<td>1.8±0.3</td>
<td>−2.0±4.7</td>
</tr>
<tr>
<td>GLP-1 0.3 pmol · kg−1 · min−1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLP-1 + saline</td>
<td>7.9±0.06</td>
<td>8.9±1.1i</td>
<td>11.7±2.7i</td>
<td>54.7±17.1i</td>
<td>6.7±1.0i</td>
<td>−23.0±2.6i</td>
</tr>
<tr>
<td>GLP-1 + ex(9-39)NH2 30</td>
<td>7.9±0.06</td>
<td>10.2±1.0i</td>
<td>7.8±1.6i</td>
<td>42.1±19.0i</td>
<td>5.0±1.2i</td>
<td>−15.7±3.4</td>
</tr>
<tr>
<td>GLP-1 + ex(9-39)NH2 60</td>
<td>7.8±0.07</td>
<td>11.8±0.8i</td>
<td>8.3±1.9i</td>
<td>38.0±13.8i</td>
<td>4.6±0.9i</td>
<td>−16.2±5.0</td>
</tr>
<tr>
<td>GLP-1 + ex(9-39)NH2 300</td>
<td>8.0±0.08</td>
<td>10.6±0.6i</td>
<td>5.0±1.2i</td>
<td>22.0±8.2i</td>
<td>3.1±0.5i</td>
<td>−7.6±3.2i</td>
</tr>
<tr>
<td>GIP-1 0.8 pmol · kg−1 · min−1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GIP + saline</td>
<td>8.0±0.07</td>
<td>−1.1±0.5</td>
<td>7.4±0.7i</td>
<td>33.5±10.2i</td>
<td>3.8±1.0i</td>
<td>−12.9±3.2i</td>
</tr>
<tr>
<td>GIP + ex(9-39)NH2 300</td>
<td>7.9±0.09</td>
<td>−1.4±0.8</td>
<td>7.3±0.8i</td>
<td>31.9±9.9i</td>
<td>3.6±1.1i</td>
<td>−5.0±2.8i</td>
</tr>
</tbody>
</table>

Mean±SEM of actual values during the last 45 min of the first infusion period (15–60 min). n = 6. *Mean increment in actual values from basal±SEM. †P < 0.05 vs. saline/saline; ‡P < 0.05 vs. GLP-1/saline; §P < 0.05 vs. GLP-1/ex(9-39)NH2 30; ¶P < 0.05 vs. GIP/saline. Doses of ex(9-39)-NH2 represent pmol · kg−1 · min−1. Keypoints are indicated in bold letters.

All samples were first tested for normality of distribution by the Kolmogoroff-Smirnoff test. Differences between experimental sets were analyzed by one-way repeated-measures ANOVA. When this analysis indicated different responses, a Student-Newman-Keuls multiple-comparison test was performed. Differences were considered significant at P < 0.05.

Results

The intravenous infusions of ex(9-39)NH2 were well tolerated in all volunteers, even upon repeated administrations.

Pooling all experiments, basal blood glucose was 4.5±0.04 mmol/liter. During the 150 min of controlled hyperglycemia, blood glucose concentrations amounted to 7.9±0.01 mmol/liter. They were stably maintained throughout this period with a variation coefficient of 4.5±0.3%.

Basal GLP-1 levels averaged 2.8±0.2 pmol/liter (Fig. 1). With intravenous infusions of GLP-1 at 0.3 and 0.9 pmol · kg−1 · min−1, plasma levels of GLP-1 dose-dependently increased. Stable plasma levels were reached within 30 min by infusion of both the low (13.0±0.5 pmol/liter) and the high (25.9±0.8 pmol/liter) load of GLP-1. Immunoreactivities of GLP-1 were

Table III. Effect of Graded Doses of Intravenous ex(9-39)NH2 on Consumption of Exogenous Glucose, Blood Glucose Levels, and Plasma Immunoreactivities of GLP-1, Insulin, C-Peptide, and Glucagon against Intravenous Background Infusions of Saline or a Supraphysiological Dose of GLP-1 during the Second Infusion Period (90–150 min) of the Hyperglycemic Clamp (8 mmol/liter) in Healthy Subjects

<table>
<thead>
<tr>
<th>Combination of intravenous infusions</th>
<th>Blood glucose</th>
<th>IR-GLP-1*</th>
<th>Glucose infusion rate</th>
<th>IR-Insulin*</th>
<th>IR-C-peptide*</th>
<th>IR-Glucagon*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mmol/liter</td>
<td>pmol/liter</td>
<td>mg/kg · min</td>
<td>mL/liter</td>
<td>ng/ml</td>
<td>pg/ml</td>
</tr>
<tr>
<td>Saline i.v.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline + saline</td>
<td>7.9±0.02</td>
<td>−2.7±0.8</td>
<td>9.1±2.2</td>
<td>26.9±7.2</td>
<td>3.9±0.6</td>
<td>−18.6±3.4</td>
</tr>
<tr>
<td>Saline + ex(9-39)NH2 30</td>
<td>7.9±0.03</td>
<td>−1.8±0.6</td>
<td>9.3±2.1</td>
<td>27.8±6.8</td>
<td>3.9±0.7</td>
<td>−19.6±4.5</td>
</tr>
<tr>
<td>Saline + ex(9-39)NH2 60</td>
<td>7.9±0.04</td>
<td>−3.6±0.7</td>
<td>8.8±2.4</td>
<td>26.1±7.6</td>
<td>3.6±0.7</td>
<td>−13.2±3.4</td>
</tr>
<tr>
<td>GLP-1 0.9 pmol · kg−1 · min−1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLP-1 + saline</td>
<td>8.0±0.05</td>
<td>21.7±1.7i</td>
<td>23.5±3.3i</td>
<td>402.6±129.5i</td>
<td>19.1±3.8i</td>
<td>−27.5±3.8i</td>
</tr>
<tr>
<td>GLP-1 + ex(9-39)NH2 30</td>
<td>8.0±0.02</td>
<td>21.8±1.3i</td>
<td>19.3±2.3i</td>
<td>300.1±142.2i</td>
<td>13.9±3.4i</td>
<td>−21.0±3.2</td>
</tr>
<tr>
<td>GLP-1 + ex(9-39)NH2 60</td>
<td>7.9±0.01</td>
<td>25.1±1.3i</td>
<td>19.4±2.6i</td>
<td>249.4±106.4i</td>
<td>12.4±3.1i</td>
<td>−20.5±5.5</td>
</tr>
<tr>
<td>GLP-1 + ex(9-39)NH2 300</td>
<td>7.9±0.04</td>
<td>24.4±1.3i</td>
<td>13.3±2.7i</td>
<td>97.1±42.5i</td>
<td>6.6±0.5i</td>
<td>−16.1±3.7i</td>
</tr>
</tbody>
</table>

Mean±SEM of actual values during the last 45 min of the second infusion period (105–150 min). n = 6. *Mean increment in actual values from basal±SEM. †P < 0.05 vs. saline/saline; ‡P < 0.05 vs. GLP-1/saline; §P < 0.05 vs. GLP-1/ex(9-39)NH2 30. Doses of ex(9-39)NH2 represent pmol · kg−1 · min−1. Keypoints are indicated in bold letters.
not changed by ex(9-39)NH₂ with or without concomitant infusion of GLP-1.

The requirement of exogenous glucose to maintain hyperglycemia dose-dependently increased with GLP-1 (Fig. 2). ex(9-39)NH₂ diminished glucose consumption at both loads of GLP-1 in a dose-dependent manner. Against a background of low-dose GLP-1, ex(9-39)NH₂ at 30 and 60 pmol · kg⁻¹ · min⁻¹ significantly reduced the glucose infusion rate by 43±25 and 41±19%, respectively. ex(9-39)NH₂ at 300 pmol · kg⁻¹ · min⁻¹ totally abolished the elevated demand for exogenous glucose (reduction by 105±10%, Table II, see Fig. 6 A). With the high load of GLP-1, glucose consumption was also substantially reduced by increasing loads of ex(9-39)NH₂ (reduction by 25±12, 26±9, and 70±6% with 30, 60, and 300 pmol · kg⁻¹ · min⁻¹, respectively). Still, it remained significantly elevated compared with saline control, even at the highest load of ex(9-39)NH₂ (Table III, see Fig. 6 B).

Pooling all experiments, basal levels of IR-insulin and IR-
C-peptide averaged 4.2±0.3 mU/liter and 1.2±0.1 ng/ml, respectively. The plasma levels of IR-insulin (Fig. 3) strongly paralleled those of IR-C-peptide. IR-insulin was dose-dependently raised to mean plasma levels of 54.7±17.1 mU/liter at the low and 402.6±129.5 mU/liter at the high load of GLP-1, respectively. ex(9-39)NH2 coinfused with GLP-1 inhibited the low and 402.6

12.9

6

1426 Schirra et al.

6

129.5 mU/liter at the high load of ex(9-39)NH2 by 84

6%. However, these levels still resided above those under saline control (Table II). In contrast, plasma insulin with high dose GLP-1 was reduced at the highest dose of ex(9-39)NH2 by 95±10%. Then, the resultant plasma levels of insulin corresponded to saline control (Fig. 4 and Table II). During the hyperglycemic clamp, ex(9-39)NH2 dose-dependently enhanced plasma glucagon. This increase of IR-glucagon was significant at the highest dose of ex(9-39)NH2 (Table II and Fig. 6 A). It already became evident at euglycemia and persisted with hyperglycemia. Remarkably, hyperglycemia still reduced IR-glucagon against a background of ex(9-39)NH2 (Fig. 5). In parallel to the elevated plasma glucagon, glucose requirement maintaining hyperglycemia was dose-dependently reduced by ex(9-39)NH2 [P < 0.05 for ex(9-39)NH2 300 pmol · kg⁻¹ · min⁻¹ vs. saline control; Table II]. The increase of insulin during hyperglycemia was significantly inhibited by ex(9-39)NH2 at the highest dose (Table II).

During the hyperglycemic clamp, ex(9-39)NH₂ dose-dependently enhanced plasma glucagon. This increase of IR-glucagon was significant at the highest dose of ex(9-39)NH₂ (Table II and Fig. 6 A). It already became evident at euglycemia and persisted with hyperglycemia. Remarkably, hyperglycemia still reduced IR-glucagon against a background of ex(9-39)NH₂ (Fig. 5). In parallel to the elevated plasma glucagon, glucose requirement maintaining hyperglycemia was dose-dependently reduced by ex(9-39)NH₂ [P < 0.05 for ex(9-39)NH₂ 300 pmol · kg⁻¹ · min⁻¹ vs. saline control; Table II]. The increase of insulin during hyperglycemia was significantly inhibited by ex(9-39)NH₂ at the highest dose (Table II).

With intravenous infusion of GIP, physiological plasma levels were achieved (2, 11). Plasma IR-GIP upon GIP infusion rose from basal levels of 150.6±25.2 pg/ml to a steady state of 616.1±27.3 pg/ml with saline, and from 176.0±55.6 to 591.2±27.3 pg/ml at the highest dose of ex(9-39)NH₂ (differences not significant). Compared with saline, GIP significantly stimulated glucose consumption as well as release of insulin and C-peptide. The insulinotropic effects of GIP were significantly smaller compared with GLP-1 (Table II). Coadministration of ex(9-39)NH₂ at 300 pmol · kg⁻¹ · min⁻¹ affected neither insulin and C-peptide responses to GIP nor the infusion rate of exogenous glucose during hyperglycemia. GIP did not influence plasma levels of glucagon. Coinfusion of ex(9-39)NH₂ and GIP caused a significant increase of plasma glucagon compared with the effect of GIP alone.

**Discussion**

This study introduces ex(9-39)NH₂ as an antagonist of GLP-1 in human. So far, ex(9-39)NH₂ was established in vitro or in animal models as a competitive antagonist at the GLP-1 recep-
tor (21, 23, 27–29). We have now provided data to define ex(9-39)NH₂ as a new tool to further characterize the significance of GLP-1 in the regulation of fuel homeostasis in humans.

Physiological postprandial plasma levels of GLP-1 were reached with the low dose of GLP-1. They were comparable to peak levels achieved after oral ingestion of a high caloric glucose meal (2, 31). With the high dose of GLP-1, supraphysiological plasma levels of GLP-1 were obtained. We can now demonstrate that ex(9-39)NH₂ dose-dependently antagonizes the effects of physiological and supraphysiological amounts of GLP-1. In this context, an important finding was that already basal circulating levels of endogenous GLP-1 apparently play a role in the control of glucagon release.

Agreeing with previous studies, infusion of GLP-1 dose-dependently increased plasma insulin and inhibited release of glucagon even during hyperglycemia (7, 8, 10, 11, 32). Accordingly, the infusion rate of glucose had to be increased with GLP-1 to maintain physiological hyperglycemia. ex(9-39)NH₂ dose-dependently reduced this elevated requirement of exogenous glucose, and at the highest dosage of the GLP-1 antagonist the increase of glucose consumption induced by low-dose GLP-1 was fully abolished. In parallel, the GLP-1–induced increase of plasma insulin and the concomitant decrease of plasma glucagon were antagonized by ex(9-39)NH₂ in a dose-dependent manner.

Recent studies with cells expressing the recombinant human (33) or rat (34) GIP receptor suggested that ex(9-39)NH₂ binds with significant affinity to the GIP receptor. At the human GIP receptor, ex(9-39)NH₂ inhibited GIP-induced cAMP accumulation with an IC₅₀ of 4.5 μmol/liter and, therefore, seemed to be a weak antagonist (24). In contrast, when infused in rats, doses of ex(9-39)NH₂ sufficient to antagonize the insulinitropic action of exogenous GLP-1 did not alter the insulinitropic effect of exogenous GIP (27, 28). However, in view of the proposed role of GIP in the entero-insulinar axis (4, 31) any possible effect of ex(9-39)NH₂ on GIP-stimulated insulin release...
secretion had to be considered in the present study. We conclusively demonstrated that there is no such effect in humans, since a high dose of ex(9-39)NH₂ that completely antagonizes the insulinotropic effect of GLP-1 does not alter the insulinotropic activity of GIP in humans (2, 11).

Recently, the presence of GLP-1 receptors on a subset of islet A cells and D cells has been suggested (35, 36). This implies that the inhibition of glucagon release by GLP-1 may be a direct effect or an indirect one via somatostatin release. In fact, exogenous GLP-1 at physiological plasma levels inhibits glucagon secretion in various species (37) including humans (7–11). An indirect suppression of glucagon by somatostatin is suggested by data revealing that GLP-1 stimulates somatostatin secretion in isolated rat and human pancreatic islets and perfused pancreas preparations (38–40). GLP-1 possesses functionally active receptors on somatostatin-secreting cells (41, 42). Therefore, glucagon secretion may be suppressed by a paracrine action induced by GLP-1, and mediated by stimulation of somatostatin secretion. Additionally, GLP-1 may influence the A cell indirectly through its stimulatory effect on the release of insulin which potently inhibits glucagon secretion (43).

Our study provides sufficient evidence that the pancreatic A cell, by whatever mechanism, is under a tonic control of GLP-1. This inhibitory influence of GLP-1 on glucagon plasma levels is dose-dependently reversed by the GLP-1 receptor antagonist. Even the lowest dose of ex(9-39)NH₂, which inhibits GLP-1-induced insulin secretion by ~25%, fully antagonized the decrease of plasma glucagon seen at the low dosage of GLP-1. Moreover, even the effects of supraphysiological plasma levels of GLP-1 on glucagon suppression were completely blocked by the antagonist. Thus, the antagonistic effect of ex(9-39)NH₂ on glucagon release was clearly more potent than that on insulin release. This suggests a dominant regulatory role for gut GLP-1 on pancreatic glucagon secretion, an action which may be mediated by somatostatin.

This is further endorsed by the observation that ex(9-39)NH₂, infused in the euglycemic state and without exogenous GLP-1, significantly increased plasma glucagon, in spite of unaltered plasma insulin. Concomitantly, blood glucose significantly rose. Our findings in humans are supported by recent findings in baboons (29) and rats (44). A tonic regulation of an islet hormone by basal concentrations of a gut hormone indicates a possible nutrient-independent fine tuning of the endocrine pancreas, at least at the interdigestive state.

Similarly, the high dose of ex(9-39)NH₂ significantly increased plasma glucagon during hyperglycemia (Fig. 5 and Table II). However, considering the plasma glucagon levels before glucose infusion, hyperglycemia reduced glucagon release to a comparable extent with or without infusion of the GLP-1 antagonist. Thus, endogenous basal GLP-1 does not add to the reduction of glucagon plasma levels induced by intravenous glucose. On the other hand, the increase of glucagon plasma levels in response to the GLP-1 antagonist was maintained even during hyperglycemia and probably contributes to the lower glucose consumption during the administration of ex(9-39)NH₂, arguably due to an increase of hepatic glucose output.

ex(9-39)NH₂ left unchanged the basal plasma levels of insulin at euglycemia. This is in agreement with previous studies in animals (28, 29). In contrast, during physiological hyperglycemia and at basal GLP-1 plasma levels, ex(9-39)NH₂ at the highest dose diminished insulin compared with hyperglycemia alone. Thus, even basal levels of endogenous GLP-1 exert a tonic stimulatory influence on the release of insulin from the B cell, but only in the presence of a simultaneous stimulation of the B cell by elevated plasma glucose. Thus, the insulinotropic action of both exogenous and endogenous GLP-1 is markedly potentiated during hyperglycemia (4, 10, 31, 45, 46).

In the rat, no effect of ex(9-39)NH₂ on glucose-stimulated insulin plasma levels was detected (28). However, in this study, such an effect occurred 30 min after onset of glucose infusion during physiological hyperglycemia. By contrast, in the study of Wang et al. (28), a short bolus of ex(9-39)NH₂ together with a high intravenous glucose load was given over 2 min. There-
fore, an unphysiological hyperglycemia could have masked the effect of ex(9-39)NH₂. In this study, the elevation of plasma glucagon and the decrease of plasma insulin may in concert explain the significantly diminished glucose consumption during hyperglycemia with the high dose of ex(9-39)NH₂.

The two low doses of ex(9-39)NH₂ at 30 and 60 pmol · kg⁻¹ · min⁻¹ were derived from in vivo studies in rat showing that an ~10-fold excess of the antagonist was necessary to completely block the action of exogenous GLP-1 (27, 28). In vitro experiments with the recombinantly expressed human GLP-1 receptor indicate a high-affinity binding of ex(9-39)NH₂ to the GLP-1 receptor (Kᵣ 1.7 nM), that was not significantly different from that of GLP-1 itself (24). In contrast, the insulinotropic effects of physiological plasma levels of GLP-1 obtained with the low load of GLP-1 during hyperglycemia were inhibited by only ~30% with ex(9-39)NH₂ at 60 pmol · kg⁻¹ · min⁻¹ and a relatively high dose of ex(9-39)NH₂ of 300 pmol · kg⁻¹ · min⁻¹, i.e., a 1,000-fold excess in relation to the GLP-1 dose, was needed to almost completely inhibit these insulinotropic effects of GLP-1. Considering the high affinity of this peptide for the human GLP-1 receptor in vitro (24), one can only speculate about a faster metabolism in plasma. We did not measure ex(9-39)NH₂ immunoreactivity due to lack of an available RIA. Therefore, the reason that such a large excess of ex(9-39)NH₂ is required in humans to fully establish antagonism against GLP-1 remains unknown. Recently, another derivative of exendin-4, exendin(3-39)amide, has been shown in rats, to be up to 10-fold more potent than ex(9-39)NH₂ in antagonizing GLP-1-stimulated insulin release (47). However, the antagonistic potency of exendin(3-39)amide in humans has to be proven.

In summary, the present data demonstrate that ex(9-39)NH₂ is a useful antagonist of GLP-1 in humans and is without agonistic properties. The use of GLP-1 receptor antagonists such as ex(9-39)NH₂ offers the possibility to really define the role of endogenous GLP-1 in the regulation of essential gastrointestinal functions, such as gastrointestinal motility, gastric emptying, and postprandial glucose homeostasis in humans. A novel observation made here is the tonic inhibition of the pancreatic A cell by basal levels of GLP-1. Furthermore, there is even stimulation of the B cell under physiological hyperglycemia by basal GLP-1.

Acknowledgments

The excellent technical assistance of Gabriele Kraft and Michaela Junck is gratefully appreciated. We thank Elisabeth Bothe and Elke Birkenstock for precise measurements of plasma hormones and Mrs. Maiszies for the sterile preparation of GLP-1 and ex(9-39)NH₂.

This work was supported by a grant from the Deutsche Forschungsgemeinschaft.

References


